详情页 - 河北大学附属医院知识库

当前位置：首页 > 详情页

Efficacy and safety of MIL60, a bevacizumab biosimilar, in combination with paclitaxel/carboplatin in patients with advanced or recurrent non-squamous non-small cell lung cancer: A randomized, double-blind, multicenter phase III study

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：

机构： [1]Department of Medical Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, China [2]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [3]Medical Oncology, Fuzhou Pulmonary Hospital of Fujian, Fuzhou, China [4]Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China [5]Department of Internal Medicine, Henan Cancer Hospital & Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China [6]Cancer Precision Medicine Center, The Affiliated Hospital of Qingdao University, Qingdao, China [7]Respiratory Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China [8]Department of Oncology Chemotherapy, The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Anhui, China [9]Oncology, Xuzhou Central Hospital, Xuzhou, China [10]Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China [11]Medical Oncology, Zhejiang Cancer Hospital, Zhejiang, China [12]Respiratory Department, The Second Hospital of Anhui Medical University, Hefei, China [13]Department of Respiratory Oncology, Gansu Province Cancer Hospital, Gansu, China [14]Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China [15]Department of Internal Oncology II, Shengjing Hospital of China Medical University, Shenyang, China [16]Internal Medicine-Oncology, Affiliated Hospital of Hebei University, Hebei, China [17]Medical Oncology Department of Thoracic Cancer, Liaoning Cancer Hospital & Institute, Shenyang, China [18]Thoracic Medicine Department II, Hunan Cancer Hospital, Changsha, China [19]Respiratory Department, Taizhou Hospital of Zhejiang Province, Taizhou, China

出处：

DOI：

ISSN：

基金：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2021]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

影响因子： 56.7 最新[2023版] 38.2 最新五年平均 51.769 出版当年[2021版] 29.61 出版当年五年平均 32.976 出版前一年[2020版] 50.5 出版后一年[2022版]

第一作者：

第一作者机构： [1]Department of Medical Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, China

推荐引用方式(GB/T 7714)：

APA：

MLA：